• 1
    Jensen DM, Damm P, Moelsted-Pedersen L, Ovesen P, Westergaard JG, Meoller M, et al. Outcomes in type 1 diabetic pregnancies: a nationwide, population-based study. Diabetes Care 2004;27:281923.
  • 2
    Persson M, Norman M, Hanson U. Obstetric and perinatal outcomes in type 1 diabetic pregnancies: a large, population-based study. Diabetes Care 2009;32:20059.
  • 3
    World Health Organization. World Health Report: Make Every Mother, and Child Count. Geneva: WHO, 2005.
  • 4
    Altman D, Carroli G, Duley L, Farrell B, Moodley J, Neilson J, et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 2002;359:187790.
  • 5
    Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:64958.
  • 6
    Chappell LC, Seed PT, Briley A, Kelly FJ, Hunt BJ, Charnock-Jones DS, et al. A longitudinal study of biochemical variables in women at risk of preeclampsia. Am J Obstet Gynecol 2002;187:12736.
  • 7
    Chappell LC, Seed PT, Briley AL, Kelly FJ, Lee R, Hunt BJ, et al. Effect of antioxidants on the occurrence of pre-eclampsia in women at increased risk: a randomised trial. Lancet 1999;354:8106.
  • 8
    Beazley D, Ahokas R, Livingston J, Griggs M, Sibai BM. Vitamin C and E supplementation in women at high risk for preeclampsia: a double-blind, placebo-controlled trial. Am J Obstet Gynecol 2005;192:5201.
  • 9
    Poston L, Briley AL, Seed PT, Kelly FJ, Shennan AH. Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP Trial): randomised placebo-controlled trial. Lancet 2006;367:114554.
  • 10
    Spinnato JA 2nd, Freire S, Pinto ESJL, Silva JL, Cunha Rudge MV, et al. Antioxidant therapy to prevent preeclampsia: a randomized controlled trial. Obstet Gynecol 2007;110:13118.
  • 11
    Rumbold AR, Crowther CA, Haslam RR, Dekker GA, Robinson JS. Vitamins C and E and the risks of preeclampsia and perinatal complications. N Engl J Med 2006;354:1796806.
  • 12
    Villar J, Purwar M, Merialdi M, Zavaleta N, Thi Nhu Ngoc N, Anthony J, et al. World Health Organisation multicentre randomised trial of supplementation with vitamins C and E among pregnant women at high risk for pre-eclampsia in populations of low nutritional status from developing countries. BJOG 2009;116:7808.
  • 13
    Roberts JM, Myatt L, Spong CY, Thom EA, Hauth JC, Leveno KJ, et al. Vitamins C and E to prevent complications of pregnancy-associated hypertension. N Engl J Med 2010;362:128291.
  • 14
    McCance DR, Holmes VA, Maresh MJ, Patterson CC, Walker JD, Pearson DW, et al. Vitamins C and E for prevention of pre-eclampsia in women with type 1 diabetes (DAPIT): a randomised placebo-controlled trial. Lancet 2010;376:25966.
  • 15
    Levy AP, Asleh R, Blum S, Levy NS, Miller-Lotan R, Kalet-Litman S, et al. Haptoglobin: basic and clinical aspects. Antioxid Redox Signal 2010;12:293304.
  • 16
    Cid MC, Grant DS, Hoffman GS, Auerbach R, Fauci AS, Kleinman HK. Identification of haptoglobin as an angiogenic factor in sera from patients with systemic vasculitis. J Clin Invest 1993;91:97785.
  • 17
    Langlois MR, Delanghe JR. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem 1996;42:1589600.
  • 18
    Costacou T, Ferrell RE, Orchard TJ. Haptoglobin genotype: a determinant of cardiovascular complication risk in type 1 diabetes. Diabetes 2008;57:17026.
  • 19
    Levy AP, Hochberg I, Jablonski K, Resnick HE, Lee ET, Best L, et al. Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: The Strong Heart Study. J Am Coll Cardiol 2002;40:198490.
  • 20
    Levy AP, Gerstein HC, Miller-Lotan R, Ratner R, McQueen M, Lonn E, et al. The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. Diabetes Care 2004;27:2767.
  • 21
    Milman U, Blum S, Shapira C, Aronson D, Miller-Lotan R, Anbinder Y, et al. Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial. Arterioscler Thromb Vasc Biol 2008;28:3417.
  • 22
    Blum S, Vardi M, Brown JB, Russell A, Milman U, Shapira C, et al. Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype. Pharmacogenomics 2010;11:67584.
  • 23
    Levy AP, Friedenberg P, Lotan R, Ouyang P, Tripputi M, Higginson L, et al. The effect of vitamin therapy on the progression of coronary artery atherosclerosis varies by haptoglobin type in postmenopausal women. Diabetes Care 2004;27:92530.
  • 24
    Weissgerber TL, Roberts JM, Jeyabalan A, Powers RW, Lee M, Datwyler SA, et al. Haptoglobin phenotype, angiogenic factors, and preeclampsia risk. Am J Obstet Gynecol 2012;206:358 e1018.
  • 25
    Gaensslen RE, Bell SC, Lee HC. Distributions of genetic markers in United States populations: III. Serum group systems and hemoglobin variants. J Forensic Sci 1987;32:175474.
  • 26
    Blum S, Milman U, Shapira C, Miller-Lotan R, Bennett L, Kostenko M, et al. Dual therapy with statins and antioxidants is superior to statins alone in decreasing the risk of cardiovascular disease in a subgroup of middle-aged individuals with both diabetes mellitus and the haptoglobin 2-2 genotype. Arterioscler Thromb Vasc Biol 2008;28:e1820.
  • 27
    Blum S, Vardi M, Levy NS, Miller-Lotan R, Levy AP. The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. Atherosclerosis 2010;211:257.
  • 28
    Brown MA, Lindheimer MD, De Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001;20:IXXIV.
  • 29
    Depypere HT, Langlois MR, Delanghe JR, Temmerman M, Dhont M. Haptoglobin polymorphism in patients with preeclampsia. Clin Chem Lab Med 2006;44:9248.
  • 30
    Raijmakers MT, Roes EM, Te Morsche RH, Steegers EA, Peters WH. Haptoglobin and its association with the HELLP syndrome. J Med Genet 2003;40:2146.
  • 31
    Sammour RN, Nakhoul FM, Levy AP, Miller-Lotan R, Nakhoul N, Awad HR, et al. Haptoglobin phenotype in women with preeclampsia. Endocrine 2010;38:3038.
  • 32
    Roberts JM, Lain KY. Recent Insights into the pathogenesis of pre-eclampsia. Placenta 2002;23:35972.
  • 33
    Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: a guideline from the American Heart Association. J Am Coll Cardiol 2011;57:140423.
  • 34
    Asleh R, Blum S, Kalet-Litman S, Alshiek J, Miller-Lotan R, Asaf R, et al. Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2-2 genotype. Diabetes 2008;57:2794800.
  • 35
    Kaneto H, Katakami N, Kawamori D, Miyatsuka T, Sakamoto K, Matsuoka TA, et al. Involvement of oxidative stress in the pathogenesis of diabetes. Antioxid Redox Signal 2007;9:35566.
  • 36
    Goldenstein H, Levy N, Levy A. Involvement of haptoglobin in prevention of oxidative stress caused by hemoglobin in preeclampsia. Adv Biosci Biotechnol 2012;3:103742.